^
BIOMARKER:

TP53 mutation + PIK3CA mutation + CD74 mutation

i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K, CD74, CD74 Molecule, CD74 Antigen (Invariant Polypeptide Of Major Histocompatibility Complex Class II Antigen-Associated), CD74 Molecule Major Histocompatibility Complex Class II Invariant Chain, HLA Class II Histocompatibility Antigen Gamma Chain, HLA-DR Antigens-Associated Invariant Chain, Gamma Chain Of Class II Antigens, Ia-Associated Invariant Chain, MHC HLA-DR Gamma Chain, HLA-DR-Gamma, DHLAG, P33, Ia Antigen-Associated Invariant Chain, CD74 Antigen, Ia-GAMMA, HLADG, II, Ii
Entrez ID:
News
Twitter
Trials
TP53 mutation + PIK3CA mutation + CD74 mutation
Lung Cancer
anlotinib
Sensitive: C4 – Case Studies
TP53 mutation + PIK3CA mutation + CD74 mutation
Lung Cancer
carboplatin + paclitaxel
Resistant: C4 – Case Studies